These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37254711)

  • 1. Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival.
    Steinmetz HT; Toczek-Thiel J; Lipke J; Liersch R; Sauer A; Tesch H; Heßling J; Totzke U; Schmitz S
    Leuk Lymphoma; 2023; 64(8):1476-1479. PubMed ID: 37254711
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
    Malcovati L
    Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of transfusion on survival in patients with myelodysplastic syndromes: Current knowledge, new insights and transfusion clinical practice.
    Kaphan E; Laurin D; Lafeuillade B; Drillat P; Park S
    Blood Rev; 2020 May; 41():100649. PubMed ID: 31918886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relevance of transfusion-dependency in the prognostic assessment of patients with myeloid neoplasms.
    Malcovati L; Cazzola M
    Am J Hematol; 2011 Mar; 86(3):241-3. PubMed ID: 21351118
    [No Abstract]   [Full Text] [Related]  

  • 5. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Retrospective analysis of treatment strategy and prognosis in childhood myelodysplastic syndromes from China and Japan].
    Chen XJ; Manabe A; Yang WY; Zhang PH; Wang SC; Guo Y; Liu F; Chang LX; Wei W; Wan Y; Zhu XF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):940-7. PubMed ID: 23998590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restrictive Versus Liberal Transfusion Strategies in Myelodysplastic Syndrome and Beyond.
    Wilde L; Pan J
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):758-762. PubMed ID: 31678078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial transfusion intensity predicts survival in myelodysplastic syndrome.
    Chan LS; Shapiro R; Buckstein R; Lin Y; Callum J; Chodirker L; Lee CD; Prica A; Lam A; Mamedov A; Wells RA
    Leuk Lymphoma; 2014 Oct; 55(10):2296-300. PubMed ID: 24397595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Myelodysplastic syndromes (MDS)].
    Germing U; Kündgen A; Haas R; Gattermann N
    Dtsch Med Wochenschr; 2012 Feb; 137(5):183-5. PubMed ID: 22278686
    [No Abstract]   [Full Text] [Related]  

  • 11. Myelodysplastic syndromes: aspects of current medical care and economic considerations in Germany.
    Gattermann N; Hofmann WK; Meessen A; Schmitz S; Tsamaloukas A; Vollmer T; Wedding U; Plesnila-Frank C; Schramm W; Berger K
    Onkologie; 2008 Sep; 31(8-9):477-84. PubMed ID: 18787357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey.
    Sekeres MA; Maciejewski JP; List AF; Steensma DP; Artz A; Swern AS; Scribner P; Huber J; Stone R
    Oncologist; 2011; 16(6):904-11. PubMed ID: 21478277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Myelodysplastic Syndromes].
    Stehle G; Schwarb H; Passweg JR
    Ther Umsch; 2019; 76(9):497-502. PubMed ID: 32157972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
    Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
    Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.
    Castelli R; Schiavon R; Deliliers GL
    Med Oncol; 2018 Feb; 35(3):33. PubMed ID: 29417235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unraveling the mysteries of MDS: linking science to practice through case studies.
    Oestreicher P
    ONS Connect; 2007; 22(8 Suppl):61-2. PubMed ID: 17824569
    [No Abstract]   [Full Text] [Related]  

  • 20. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
    de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
    Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.